Abstract:Hua Liu, 1, 2, &ast Yang-Min Hao, 1, 2, &ast Sheng Jiang, 1, 2, &ast Maiheliya Baihetiyaer, 1, 2 Cheng Li, 3 Guo-Yao Sang, 4 Zhiming Li, 5 Guo-Li Du 1, 2, 6 1 State Key Laboratory of Pathogenesis, Prevention, and Treatment of High Incidence Diseases in Central Asia, Urumqi, Xinjiang, People's Republic of China; 2 Department of Endocrinology, First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, People's Republic of China; 3 Data Statistics and Analysis Center of Operation Management Department, First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, People's Republic of China; 4 Laboratory Medicine Diagnostic Center, First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, People's Republic of China; 5 Department of Ultrasound, First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, People's Republic of China; 6 Bazhou People's Hospital, Korla, Xinjiang Uygur Autonomous Region, People's Republic of China &astThese authors contributed equally to this work Correspondence: Guo-Li Du, Email Purpose: This study aims to investigate the relationship between Sodium Glucose Co-transporter-2 inhibitors (SGLT2i) treatment and fibrosis in patients with Metabolic dysfunction-associated steatotic liver disease (MASLD) combined with Type 2 Diabetes Mellitus (T2DM) and Major Adverse Cardiovascular and Cerebrovascular Events (MACCEs). Methods: A case–control study was conducted, involving 280 patients with MASLD combined with T2DM treated at the First Affiliated Hospital of Xinjiang Medical University from January 2014 to October 2023. Among these patients, 135 received SGLT2i treatment. The association between the Fibrosis-4 (FIB-4) index and the occurrence of MACCEs, as well as the association between the Aspartate Aminotransferase-to-Platelet Ratio Index (APRI) scores and MACCEs, were evaluated. Results: The FIB-4 index and APRI scores were significantly lower in the SGLT2i treatment group compared to the non-SGLT2i group (1.59 vs 1.25, P < 0.001). SGLT2i treatment tended to reduce the occurrence of MACCEs compared to non-SGLT2i treatment (45.5% vs 38.5%, P =0.28). All patients who developed MACCEs in the non-SGLT2i treatment group had higher FIB-4 index (1.83 vs 1.35, P =0.003). Additionally, after SGLT2i treatment for a median duration of 22 months, patients showed significant reductions in blood glucose, APRI, and FIB-4 index. Conclusion: SGLT2i treatment significantly reduces the occurrence of MACCEs and liver fibrosis in patients with MASLD combined with T2DM. The FIB-4 index may serve as a potential surrogate marker for predicting the occurrence of MACCEs. Keywords: MASLD, type 2 diabetes mellitus, sodium-glucose co-transporter-2 inhibitors, MACCEs, FIB-4 index With the improvement of living standards, diabetes mellitus has become one of the most common chronic diseases in the world widely. 1 T2DM (Type 2 diabetes mellitus) is closely associated with cardiovascular diseases (CVD), including atherosclerosis, hypertension and heart failure. 2 CVD is the main cause of disability and disease burden globally, leading to premature mortality and increased health care costs. 3 Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly referred to as non-alcoholic fatty liver disease (NAFLD), is recognized globally as a significant cause of chronic liver disease. The diagnosis of MASLD includes evidence of liver steatosis and at least one of the following five cardiac metabolic criteria: overweight or obesity, impaired glucose regulation or T2DM, hypertension, increased plasma triglycerides (TG) or decreased high-density lipoprotein cholesterol (HDL-c). 4 T2DM has long been recognized as an independent cardiovascular risk factor and is a common finding in MASLD. Approximately 60% of patients with T2DM have MASLD. 5,6 Furthermore, patients with T2DM combined with MASLD had a higher risk of CVD compared with patients with T2DM alone. This suggests a potential synergistic effect on cardiovascular disease occurrence in patients. 7,8 In the majority of patients, MASLD is closely associated with insulin resistance, hypertension, atherogenic dyslipidaemia, dysglycaemia and being overweight or obese, which are all established risk factors for CVD. 9–11 Conversely, previous studies have shown that the main cause of death in MASLD patients is CVD. 12 In addition, it is estimated that 20–30% of pat -Abstract Truncated-

Blood -glycomic signature of fibrosis in MASLD shows low levels of global α2,3-sialylation

Comprehensive meta-analysis reveals distinct gene expression signatures of MASLD progression

Plasma ALS and Gal-3BP differentiate early from advanced liver fibrosis in MASLD patients

Distinct Gut Microbial Signature and Host Genetic Variants in Association with Liver Fibrosis Severity in Patients with MASLD

From NAFLD to MASLD: when Metabolic Comorbidity Matters.

Disruption of gut barrier integrity and host–microbiome interactions underlie MASLD severity in patients with type-2 diabetes mellitus

Spatial Omics Reveals that Cancer-Associated Glycan Changes Occur Early in Liver Disease Development in a Western Diet Mouse Model of MASLD

Identification of signature gene set as highly accurate determination of MASLD progression

Multiscale integrative analyses unveil immune-related diagnostic signature for the progression of MASLD

Pharmacogene expression during progression of metabolic dysfunction-associated steatotic liver disease: Studies on mRNA and protein levels and their relevance to drug treatment

Use of PNPLA3, TM6SF2, and HSD17B13 for detection of fibrosis in MASLD in the general population

Deep Proteome Profiling of Metabolic Dysfunction-Associated Steatotic Liver Disease

MASLD in people with HIV exhibits higher fibrosis stage despite lower disease activity than in matched controls

Organ damage proteomic signature identifies patients with MASLD at-risk of systemic complications.

Metabolic Dysfunction-Associated Steatotic Liver Disease: The Associations Between Inflammatory Markers, TLR4, and Cytokines IL-17A/F, and their Connections to the Degree of Steatosis and the Risk of Fibrosis

Evaluation of MASLD Fibrosis, FIB-4 and APRI Score in MASLD Combined with T2DM and MACCEs Receiving SGLT2 Inhibitors Treatment

A prognostic molecular signature of hepatic steatosis is spatially heterogeneous and dynamic in human liver

Blood glucose control and metabolic dysfunction-associated steatotic liver disease in people with type 1 diabetes

Circulating mitochondrial bioenergetic profile reflects the hepatic one and represents a non-invasive biomarker of disease severity in MASLD genetically predisposed individuals

Elevated serum growth differentiation factor 15 and decorin predict the fibrotic progression of metabolic dysfunction-associated steatotic liver disease

Mycobiome Dysbiosis and Genetic Predisposition for Elevated IL-17A Drive Fibrosis in MASLD